Survival outcome of neoadjuvant endocrine therapy plus trastuzumab and pertuzumab (ET plus T plus P) vs. de-escalated chemotherapy (CT) plus T plus P in hormone receptor positive (HR+)/HER2+early breast cancer (EBC): WSG-TP-II trial

被引：0
|
作者：
Gluz, O. [1 ]
Nitz, U. A. [2 ]
Christgen, M. [3 ]
Kummel, S. [4 ]
Holtschmidt, J. [5 ]
Schumacher, J. [6 ]
Hartkopf, A. D. [7 ]
Luedtke-Heckenkamp, K. [8 ]
Just, M. [9 ]
von Schumann, R. [10 ]
Polata, S. [11 ]
Schinkoethe, T. [12 ]
Graeser-Mayer, M. K. [13 ]
Kates, R. E. [14 ]
Wuerstlein, R. [15 ]
Kreipe, H. [3 ]
Harbeck, N. [16 ]
机构：
[1] Evangeliches Krankenhaus Bethesda Klin, Breast Ctr, Monchengladbach, Germany
[2] West German Study Grp, Senol, Monchengladbach, Germany
[3] MHH, Pathol, Hannover, Germany
[4] Kliniken Essen Mitte Evang Huyssens Stiftung, Breast Unit, Essen, Germany
[5] St Elisabeth Clin Hohenlind, Breast Ctr, Cologne, Germany
[6] Palleos GmbH, Stat, Wiesbaden, Germany
[7] Univ Hosp Tubingen, Ctr Womens Hlth, Tubingen, Germany
[8] Niels Stensen Kliniken GmbH, Franziskus Hosp Harderberg, Oncol Dept, Georgsmarienhutte, Germany
[9] Onkol Schwerpunkt Praxis, Oncol, Greifswald, Germany
[10] Johanniter Bethesda Moenchengladbach, Breast Ctr Niederrhein, Monchengladbach, Germany
[11] Oncol Ctr Spandau, Oncol, Berlin, Germany
[12] LMU Klinikum Univ Munchen, Breast Ctr, Munich, Germany
[13] Westdeutsch Studiengrp GmbH, Senol, Monchengladbach, Germany
[14] Westdeutsch Studiengrp GmbH, Breast Ctr Dept, Monchengladbach, Germany
[15] LMU Klinikum Univ Munchen, Breast Ctr Dept, Munich, Germany
[16] LMU Univ Hosp, Dept Obstet & Gynecol, Breast Ctr, Munich, Germany
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.2255
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA17
引用
收藏
页码：1210 / 1210
页数：1
相关论文
共 50 条
  • [11] Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel plus carboplatin plus trastuzumab plus pertuzumab in HER2+early breast cancer: WSG-ADAPT-HER2-IV.
    Harbeck, Nadia
    Braun, Michael
    Gluz, Oleg
    Schmid, Peter
    Graeser, Monika Karla
    Hartkopf, Andreas D.
    Hoffmann, Oliver
    Kostara, Athina
    Polata, Silke
    Volmer, Lea Louise
    von Schumann, Raquel
    Wetzig, Sarah
    Wiebe, Stefanie
    Zaiss, Matthias R.
    Fischer, Lotta Ada
    Scheffen, Iris
    Christgen, Matthias
    Kreipe, Hans Heinrich
    Nitz, Ulrike
    Kuemmel, Sherko
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [12] Impact of immune markers on response to neoadjuvant de-escalated T-DM1 or trastuzumab with/or without endocrine therapy in HR+/HER2+early breast cancer: A translational subproject of the WSG-ADAPT-HER2+/HR+ trial
    Biehl, Claudia
    Kolberg-Liedtke, Cornelia
    Gluz, Oleg
    Feuerhake, Friedrich
    Christgen, Matthias
    Kates, Ronald
    Grischke, Eva-Maria
    Forstbauer, Helmut
    Braun, Michael
    Warm, Mathias
    Hackmann, John
    Uleer, Christoph
    Aktas, Bahriye
    Schumacher, Claudia
    Kuemmel, Sherko
    de Haas, Sanne L.
    Deurloo, Regula
    Wuerstlein, Rachel
    Nitz, Ulrike
    Kreipe, Hans H.
    Harbeck, Nadia
    CANCER RESEARCH, 2020, 80 (04)
  • [13] Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) plus trastuzumab (H) plus placebo (Pla) versus C plus H plus pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC).
    Baselga, Jose
    Petersen, Jennifer A.
    Clark, Emma
    Barton, Claire
    Restuccia, Eleonora
    Procter, Marion Jennifer
    Sonnenblick, Amir
    Fumagalli, Debora
    Parlier, Damian
    Arahmani, Amal
    Viale, Giuseppe
    Reaby, Linda L.
    Frank, Elizabeth
    Gelber, Richard D.
    Piccart-Gebhart, Martine J.
    Bines, Jose
    von Minckwitz, Gunter
    Gasper, Sabina McGarrahan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [14] De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
    Nitz, Ulrike
    Gluz, Oleg
    Graeser, Monika
    Christgen, Matthias
    Kuemmel, Sherko
    Grischke, Eva-Maria
    Braun, Michael
    Augustin, Doris
    Potenberg, Jochem
    Krauss, Katja
    Schumacher, Claudia
    Forstbauer, Helmut
    Reimer, Toralf
    Stefek, Andrea
    Fischer, Hans Holger
    Pelz, Enrico
    Zu Eulenburg, Christine
    Kates, Ronald
    Wuerstlein, Rachel
    Kreipe, Hans Heinrich
    Harbeck, Nadia
    LANCET ONCOLOGY, 2022, 23 (05): : 625 - 635
  • [15] ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEE followed by paclitaxel plus trastuzumab (FEC → P plus T) with paclitaxel plus trastuzumab followed by EEC plus trastuzumab (P plus T → FEC+T) in HER2+operable breast cancer
    Buzdar, Aman
    Suman, Vera J.
    Meric-Bernstam, Funda
    Leitch, A. Marilyn
    Ellis, Matthew James
    Boughey, Judy Caroline
    Unzeitig, Gary Walter
    Royce, Melanie
    Hunt, Kelly
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [16] Predictive value of HER2 expression, early response and tumor infiltrating lymphocytes (TILs) on efficacy of de-escalated pertuzumab plus trastuzumab in the neoadjuvant WSG-ADAPT-HER2+/HR-trial
    Gluz, Oleg
    Kolberg-Liedtke, Cornelia
    Biehl, Claudia
    Christgen, Matthias
    Kuemmel, Sherko
    Grischke, Eva -Maria
    Augustin, Doris
    Braun, Michael
    Potenberg, Jochem
    Graeser, Monika
    Kates, Ronald
    Wuerstlein, Rachel
    Feuerhake, Friedrich
    Nitz, Ulrike
    Kreipe, Hans
    Harbeck, Nadia
    CANCER RESEARCH, 2020, 80 (04)
  • [17] Disease-free (DFS) and overall survival (OS) data from ACOSOG Z1041 (Alliance) a randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P plus T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P plus T → FEC+T) in HER2-positive operable breast cancer
    Buzdar, A. U.
    Suman, V. J.
    Meric-Bernstam, F.
    Leitch, A. M.
    Ellis, M. J.
    Boughey, J. C.
    Unzeitig, G. W.
    Royce, M. E.
    Ewer, M. S.
    Hunt, K. K.
    CANCER RESEARCH, 2016, 76
  • [18] A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel plus carboplatin plus trastuzumab plus pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
    Masuda, Norikazu
    Ohtani, Shoichiro
    Takano, Toshimi
    Inoue, Kenichi
    Suzuki, Eiji
    Nakamura, Rikiya
    Bando, Hiroko
    Ito, Yoshinori
    Ishida, Kazushige
    Yamanaka, Takashi
    Kuroi, Katsumasa
    Yasojima, Hiroyuki
    Kasai, Hiroi
    Takasuka, Tsuyoshi
    Sakurai, Takaki
    Kataoka, Tatsuki R.
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (01) : 135 - 146
  • [19] Final overall survival (OS) for abemaciclib plus trastuzumab plus /- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+advanced breast cancer (monarcHER): A randomized, open-label, phase II trial
    Andre, F.
    Nadal, J. C.
    Denys, H.
    Goel, S.
    Litchfield, L. M.
    Appiah, A.
    Chen, Y.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1386 - S1387
  • [20] Neratinib plus fulvestrant plus trastzuzumab (N plus F plus T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.
    Jhaveri, Komal L.
    Goldman, Jonathan W.
    Hurvitz, Sara A.
    Guerrero-Zotano, Angel
    Unni, Nisha
    Brufsky, Adam
    Park, Haeseong
    Waisman, James Ross
    Yang, Eddy Shih-Hsin
    Spanggaard, Iben
    Reid, Sonya A.
    Burkard, Mark E.
    Prat, Aleix
    Loi, Sherene
    Crown, John
    Hanker, Ariella
    Ma, Cynthia X.
    Bose, Ron
    Eli, Lisa DeFazio
    Wildiers, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345